Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.

ABSTRACT:

Rationale

Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia.

Objective

This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once-monthly in non-acute but symptomatic adult patients switched from previously unsuccessful monotherapy with frequently used oral atypical antipsychotics.

Methods

This was a post hoc analysis of a prospective, interventional, single-arm, international, multicenter, open-label, 6-month study.

Results

The patients (N = 472) were switched to paliperidone palmitate once-monthly (PP1M) from daily oral treatment with either aripiprazole (n = 46), olanzapine (n = 87), paliperidone extended-release (n = 104), quetiapine (n =

SUBMITTER: Schreiner A 

PROVIDER: S-EPMC5203852 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature